Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Imran Shaikh

Internal Medicine Quincy, IL Medical Doctor

NPI 1699120535 CMS profile 8392453

1025 Maine St, Quincy, IL 62301

Open in the dashboard

General payments

$7,506

268 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Imran Shaikh of Quincy, IL is reported in the CMS Open Payments database as having received $7,506 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,711 89
2024 General $1,098 49
2023 General $1,320 52
2022 General $2,542 51
2021 General $806 25
2020 General $29 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Imran Shaikh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Imran Shaikh were reported at $1,711. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Imran Shaikh Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $29 $119 $33–$402 $114
2021 $806 $135 $37–$521 $132
2022 $2,542 $141 $42–$496 $149
2023 $1,320 $149 $45–$519 $160
2024 $1,098 $154 $47–$537 $164
2025 $1,711 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Inspire Medical Systems, Inc. $2,448 14 payments
  2. Harmony Biosciences LLC $1,107 66 payments
  3. Jazz Pharmaceuticals Inc. $810 38 payments
  4. Amgen Inc. $460 25 payments
  5. Novo Nordisk Inc $352 24 payments
  6. AstraZeneca Pharmaceuticals LP $309 15 payments
  7. Preventric Diagnostics, Inc. $298 1 payment
  8. Lilly USA, LLC $280 17 payments
  9. Avadel CNS Pharmaceuticals, LLC $180 9 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $136 8 payments
  11. Other $1,126 51 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $6,212 263 payments
  2. Travel and Lodging $1,079 1 payment
  3. Education $190 2 payments
  4. Debt forgiveness $24 2 payments
Products named General payments · program years 2020–2025
  1. Inspire Upper Airway Stimulation System $1,728 2 payments
  2. XYWAV $810 38 payments
  3. INSPIRE $719 12 payments
  4. WAKIX Narcolepsy $349 29 payments
  5. Repatha $344 18 payments
  6. BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM $298 1 payment
  7. WAKIX Narcoplepsy $298 14 payments
  8. Ozempic $275 18 payments
  9. RYBELSUS $275 18 payments
  10. Otezla $260 15 payments
  11. Other $3,403 178 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 138 drugs

Part D claims

9,039

Median for Hospitalist: 109

Drug cost

$593,938

Median for Hospitalist: $6,399

Branded share of claims

20.6%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 117 $119,853
Ozempic Semaglutide Brand 97 $103,842
Jardiance Empagliflozin Brand 48 $48,677
Eliquis Apixaban Brand 35 $33,277
Trulicity Dulaglutide Brand 31 $30,136
Xarelto Rivaroxaban Brand 24 $26,356
Januvia Sitagliptin Phosphate Brand 31 $24,783
Farxiga Dapagliflozin Propanediol Brand 21 $23,106
Tresiba Flextouch U-200 Insulin Degludec Brand 26 $17,986
Rybelsus Semaglutide Brand 13 $17,672

The 10 drugs with the highest cost, of 138 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$105,556

Medicare's payments for the services billed

Medicare patients

275

Average age 71

Services billed

788

135 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 35%
Ischemic heart disease 33%
Atrial fibrillation 29%
Depression 28%
COPD 24%
Chronic kidney disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $298
$298 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $244
$244 — —
LUMRYZ
  • Avadel CNS Pharmaceuticals, LLC $78
$78 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $67
$67 21 —
SPIRIVA RESPIMAT
  • Boehringer Ingelheim Pharmaceuticals, Inc. $25
$25 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record